share_log

Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

Stifel以買入評級啓動對Cullinan Therapeutics的報道,宣佈目標股價爲40美元
Benzinga ·  05/01 05:49

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $40.

Stifel分析師布拉德利·卡尼諾以買入評級啓動了對庫裏南療法(納斯達克股票代碼:CGEM)的報道,並宣佈目標股價爲40美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論